Impact Wealth Magazine recently covered Verseon praising its clinical-stage drug development programs addressing eight major diseases. Verseon developed its advanced AI- and Physics-driven platform for drug discovery and has recently adapted technology from its clinical-trials AI for use in its upcoming anti-aging healthspan support service.
—
Fremont, Calif.—Verseon is pleased to announce recent coverage that the company has received from Impact Wealth Magazine for its healthspan products and its innovative new drug development programs addressing major diseases. Verseon has pioneered the use of AI and physics for systematic design and development of new drugs, and the company’s mission is to use its scientific and technological advancements to redefine the delay, prevention, and treatment of disease.
Already a clinical-stage pharmaceutical company with eight major disease programs underway, Verseon recently adapted technology from its clinical-trials AI for use in its upcoming anti-aging healthspan support service. The company’s purpose-built AI system will customize for each subscriber an evidence-based combination of active ingredients to combat all nine hallmarks of aging. The service will continually optimize this combination based on its growing outcomes database. Verseon brings the same scientific expertise and rigor it has developed for its pharmaceutical drug programs to its healthspan support service as the company seeks to not only treat diseases but also delay or even prevent their onset.
For its pharmaceutical drug programs, Verseon’s multiphysics-augmented AI platform systematically develops multiple chemically distinct drug candidates that no other current method can find. These candidates show highly desirable treatment profiles and promise to positively impact the lives of hundreds of millions around the globe.
Among the promising pharmaceutical candidates the company is developing are anticoagulants with very low bleeding risk to safely treat and prevent heart attacks and strokes in over 400 million people worldwide. Current blood thinners pose bleeding risks that are too high for long-term use. The company’s oral diabetic retinopathy drug candidates open the possibility of preventing vision loss in over 154 million diabetics worldwide before symptoms progress.
Verseon is also addressing cancer on multiple fronts. Currently, the company has 3 cancer programs, including one to develop chemotherapy agents that do not lose effectiveness against multidrug-resistant cancers.
About Verseon
To advance global health, Verseon International Corporation (www.verseon.com) has created a better, more scalable process for designing and developing new drugs addressing currently untreatable or poorly treated conditions. The company’s drug development platform incorporates fundamental advancements in molecular modeling, directed synthesis, integrated translational research and AI to develop drug compounds that have never before been synthesized—and are virtually impossible to find using conventional methods. Verseon is a clinical-stage company with a growing pipeline that currently includes seven drug programs in the areas of anticoagulation, diabetic retinopathy, hereditary angioedema, oncology, and metabolic disorders.
Contact Info:
Name: Walter Jones
Email: Send Email
Organization: Verseon
Address: 47000 Warm Springs Boulevard, Fremont, CA 94539, United States
Website: https://www.verseon.com
Release ID: 89073707
